Biological medicines have markedly changed the prognoses for many chronic and disabling inflammatory and immunological conditions and cancers. Their use in New Zealand is increasing and, as patents expire on reference or originator “biologics”, the opportunity arises for competitor manufacturers to list biosimilars – highly similar versions of approved biological medicines